Article Sidebar

PDF (Tiếng Việt)
Published: 2025-07-28
Abstract Views: 0
Views PDF (Tiếng Việt): 0
DOI: https://doi.org/10.52852/tcncyh.v192i7.3679
Issue
Vol. 192 No. 7 (2025)
Section
Các bài báo
How to Cite
Hoa, N. D., Giang, Đào P., Huyền, N. T. T., Hạnh, Đỗ T., Hảo, N. T., Dung, Đặng T. N., Bích, Đặng T., & Hoàn, N. X. (2025). 12. Evaluation of miRNA-29a-5p expression and its association with clinical and paraclinical characteristics in hbv-related hepatocellular carcinoma, liver cirrhosis and chronic hepatitis patients. Journal of Medical Research, 192(7), 103-114. https://doi.org/10.52852/tcncyh.v192i7.3679

12. Evaluation of miRNA-29a-5p expression and its association with clinical and paraclinical characteristics in hbv-related hepatocellular carcinoma, liver cirrhosis and chronic hepatitis patients

Ngo Dieu Hoa, Dao Phuong Giang, Nguyen Thi Thanh Huyen, Do Thuy Hanh, Nguyen Thi Hao, Dang Thi Ngoc Dung, Dang Thi Bich, Nghiem Xuan Hoan

Main Article Content

Abstract

This study aimed to evaluate the diagnostic value of miRNA-29a-5p in hepatocellular carcinoma (HCC), particularly in early-stage disease and in the context of chronic liver disease caused by HBV infection. A cross-sectional descriptive study was conducted, quantifying serum miRNA-29a-5p levels using qPCR in two phases: screening (30 patients) and validation (300 patients). The results showed that miRNA-29a-5p was significantly overexpressed in the HCC group compared to the hepatitis B and cirrhosis groups, with corresponding fold-changes of 2.69 and 2.07 (p < 0.001). The area under the curve (AUC) of miRNA-29a-5p for distinguishing HCC from chronic hepatitis B was 0.677 (p < 0.001), and for distinguishing HCC from cirrhosis was 0.758, which was higher than AFP (AUC = 0.729). In patients with HCC, when comparing the expression levels of miRNA-29a-5p between the two groups with AFP ≤ 20 ng/mL and > 20 ng/mL, the difference was statistically significant (p = 0.032).

Article Details

Keywords

miRNA, hepatocellular carcinoma, cirrhosis, chronic hepatitis B, hepatitis B virus

References

1. Torresi J, Locarnini S. Antiviral chemotherapy for the treatment of hepatitis B virus infections. Gastroenterology. 2000; 118(2 Suppl 1): S83-103. doi:10.1016/s0016-5085(00)70008-4.
2. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012; 142(6): 1264-1273.e1. doi:10.1053/j.gastro.2011.12.061.
3. Yang YL, Chang YH, Li CJ, et al. New Insights into the Role of miR-29a in Hepatocellular Carcinoma: Implications in Mechanisms and Theragnostics. J Pers Med. 2021; 11(3): 219. doi:10.3390/jpm11030219.
4. Fabbri M, Garzon R, Cimmino A, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci. 2007; 104(40): 15805-15810. doi:10.1073/pnas.0707628104.
5. Dương ĐC. Nghiên cứu biểu hiện microRNA-21, microRNA-122 huyết tương ở bệnh nhân ung thư biểu mô tế bào gan nhiễm vi rút viêm gan B. Trang Luận Văn Luận Án Bộ Giáo Dục Và Đào Tạo. Published online 2020. Accessed October 22, 2022. https://thuvienso.quochoi.vn/handle/11742/57673.
6. Bộ Y tế. Quyết định 3310/QĐ-BYT 2019 hướng dẫn chẩn đoán điều trị bệnh viêm gan vi rút B. 2019. Accessed March 13, 2024. https://thuvienphapluat.vn/van-ban/The-thao-Y-te/Quyet-dinh-3310-QD-BYT-2019-huong-dan-chan-doan-dieu-tri-benh-viem-gan-vi-rut-B-419819.aspx.
7. Bộ Y tế. Quyết định 3129/QĐ-BYT 2020 tài liệu Hướng dẫn chẩn đoán điều trị ung thư biểu mô tế bào gan. Published online 2020.
8. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update - PubMed. Accessed March 6, 2025. https://pubmed.ncbi.nlm.nih.gov/34801630/
9. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods San Diego Calif. 2001; 25(4): 402-408. doi:10.1006/meth.2001.1262.
10. Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022; 76(3): 681-693. doi:10.1016/j.jhep.2021.11.018.
11. Licursi V, Conte F, Fiscon G, Paci P. MIENTURNET: an interactive web tool for microRNA-target enrichment and network-based analysis. BMC Bioinformatics. 2019; 20(1): 545. doi:10.1186/s12859-019-3105-x.
12. Han X, Zheng J, Wang Y, Gao Z. miRNA-29a inhibits colon cancer growth by regulation of the PTEN/Akt/GSK3β and Wnt/β-catenin signaling pathways. Oncol Lett. 2018; 16(2): 2638-2644. doi:10.3892/ol.2018.8905.
13. Upregulated MicroRNA-29a by Hepatitis B Virus X Protein Enhances Hepatoma Cell Migration by Targeting PTEN in Cell Culture Model | PLOS One. Accessed March 5, 2025. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0019518.
14. Xiao Z, Wang Y, Ding H. XPD suppresses cell proliferation and migration via miR-29a-3p-Mdm2/PDGF-B axis in HCC. Cell Biosci. 2019; 9(1): 6. doi:10.1186/s13578-018-0269-4.
15. Li Y, Ma H, Shi C, Feng F, Yang L. Mutant ACTB mRNA 3′-UTR promotes hepatocellular carcinoma development by regulating miR-1 and miR-29a. Cell Signal. 2020; 67: 109479. doi:10.1016/j.cellsig.2019.109479.
16. Lin XJ, Chong Y, Guo ZW, et al. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. Lancet Oncol. 2015; 16(7): 804-815. doi:10.1016/S1470-2045(15)00048-0.
17. Zhu HT, Dong QZ, Sheng YY, et al. MicroRNA-29a-5p Is a Novel Predictor for Early Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma after Surgical Resection. PLOS ONE. 2012; 7(12): e52393. doi:10.1371/journal.pone.0052393.